Vanguard Capital Management
SNTI icon

Vanguard Capital Management’s Senti Biosciences Holdings SNTI Stock Holding History

Vanguard Capital Management’s Portfolio SNTI Stock Details SNTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$591K Hold
537,504
– – ﹤0.01% 3687
2026
Q1 		$436K Buy
+537,504
New +$520K ﹤0.01% 3698

Other funds holding SNTI

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
MVM
Menlo Ventures Management Menlo Park, California $357M AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Vanguard Capital Management's SNTI Position: Q2 2026 in Review

Vanguard Capital Management held its Senti Biosciences Holdings (SNTI) position steady in Q2 2026 at 537,504 shares worth $591K. The position accounts for ﹤0.01% of the portfolio, ranked #3687.

Vanguard Capital Management first reported a position in SNTI in Q1 2026 and has held it in 2 quarters since. 17 funds tracked by Wall St. Rank hold SNTI as of Q2 2026.

  • Vanguard Capital Management held 537,504 shares of Senti Biosciences Holdings worth $591K as of Q2 2026.
  • Vanguard Capital Management left its Senti Biosciences Holdings share count unchanged in Q2 2026.
  • Senti Biosciences Holdings made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3687 holding.
  • Vanguard Capital Management first reported a position in Senti Biosciences Holdings in Q1 2026 and has held it in 2 quarters since.
  • 17 funds tracked by Wall St. Rank held Senti Biosciences Holdings as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.